The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Rinvoq (upadacitinib)
Australian Public Assessment Report
Device/Product Name
Rinvoq
Active ingredients
Upadacitinib
AusPAR Date
Published
Sponsor
Submission Number
PM-2022-00116-1-3
Submission Type
Extension of indication
Decision
Approved